DEEP BRAIN STIMULATION DEVICES MARKET ANALYSIS

Deep Brain Stimulation Devices Market Size and Trends

The Global Deep Brain Stimulation Devices Market is estimated to be valued at USD 1.50 billion in 2024 and is expected to reach USD 3.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.5% from 2024 to 2031.

Key Takeaways of the Deep Brain Stimulation Devices Market:

• By Product Type, Single-channel DBS Devices segment contributes the highest share of the market with 52.1% in 2024.
• By Application, Epilepsy contributes the highest share of the market with 36.2% in 2024.
• By End User, Hospitals contributes the highest share of the market with 40.1% in 2024.
• North America to top the global market with 38.4% share, followed by Asia Pacific with 27.7% share in 2024.

Market Overview

The deep brain stimulation devices market is witnessing positive trends with major players continuously innovating and launching new products with enhanced features. Technological advancements have allowed improved targeting abilities and battery lives in these devices. Further miniaturization of deep brain stimulators along with the integration of biosensors is expected to make the treatment safer and more effective. This is anticipated to boost the adoption of deep brain stimulation especially for neurological conditions.

To learn more about this report, Request sample copy

Top Strategies Followed by Global Deep Brain Stimulation Devices Market Players

• Established Players: Leading players in the global deep brain stimulation devices market heavily invest in research and development to drive product innovation. Medtronic, for instance, spends over US$ 2 billion annually on R&D with the aim of developing cutting-edge neurostimulation technologies. Boston Scientific expands its R&D capabilities through acquisitions and partnerships to introduce advanced DBS systems for difficult-to-treat neurological disorders.
• Mid-Level Players: These companies focus on delivering quality, budget-friendly products targeting price-sensitive consumers. For example, Aleva Neurotherapeutics offers innovative DBS systems designed to be cost-effective, catering to a broader patient demographic. Partnerships aimed at boosting technology and production capabilities are common. NeuroOne Medical Technologies has collaborated with Zimmer Biomet to enhance its electrode technology, aiming to improve patient outcomes and expand its market presence.
• Small-Scale Players: Smaller companies often target niche markets with unique features. For instance, InBrain Neuroelectronics is developing graphene-based brain implants, aiming to provide more effective and less invasive DBS solutions. Collaborations with local manufacturers help gain market entry. For example, Beijing Pins Medical has partnered with local healthcare providers to introduce its DBS systems into the Chinese market, enhancing visibility and adoption.

Emerging Startups - Deep Brain Stimulation Devices Industry Ecosystem

• Innovative Technologies: Several startups are actively working on next-gen DBS technologies. Kernel, a neurotech startup, is developing a neural implant and companion app to non-invasively treat neurological disorders. Another example is NeuroPace, which created the RNS System - the first FDA-approved brain stimulator for epilepsy.
• Sustainable Solutions: Startups like Anthropic focus on designing AI-powered brain implants that can be recycled and remanufactured sustainably. Greensboro, Alabama-based MyndYou is creating biodegradable, plant-based materials for brain implants reducing health and environmental risks.
• Some startups are targeting niche, underserved segments in the market. For example, Flow Neuroscience focuses on treating psychiatric conditions such as OCD and PTSD through localized brain stimulation. The company collaborates with research institutions to validate its innovative, non-invasive techniques. Similarly, the early-stage startup Synchron specializes in restoring motor functions lost after a stroke by utilizing spinal cord stimulation, developed in partnership with leading healthcare organizations.

Key Developments:

• In September 2024, Abbott, a global healthcare leader known for its innovative medical devices, launched the TRANSCEND study, a pivotal clinical trial to evaluate the efficacy of its DBS system in treating treatment-resistant depression (TRD), a severe form of major depressive disorder
• In September 2024, Medtronic, a pioneer in medical technology, released the trial design and preliminary findings of the ADAPT-PD trial, which focuses on the use of an adaptive DBS algorithm to deliver personalized therapy for Parkinson's disease
• In January 2024, Abbott received the U.S. FDA approval for its Liberta RC DBS system, the world’s smallest rechargeable DBS device. This innovative system features remote programming capabilities and is designed to improve the quality of life for people living with movement disorders.
• In January 2024, Medtronic gained the U.S. FDA approval for its Percept RC Deep Brain Stimulation (DBS) system. This rechargeable neurostimulator is the latest addition to the Percept family, which includes SenSight directional leads and BrainSense technology for advanced neurological care.
• In January 2021, Boston Scientific, a leading medical device company specializing in DBS systems, received the U.S. FDA approval for its fourth-generation Vercise Genus DBS System. The portfolio includes Bluetooth-enabled, rechargeable and non-rechargeable implantable pulse generators compatible with Cartesia Directional Leads, designed for optimized symptom relief and approved for conditional use in MRI environments.